A Second Opinion From Observational Data on Second-Line Diabetes Drugs

JAMA network open - United States
doi 10.1001/jamanetworkopen.2018.6119
Full Text
Abstract

Available in full text

Categories
Medicine
Date
Authors
Publisher

American Medical Association (AMA)

Related search

Second Opinion

Pediatric Cardiology
Child HealthPediatricsCardiovascular MedicinePerinatologyCardiology
2015English

Insulin for Type 2 Diabetes: Choosing a Second-Line Insulin Regimen

International Journal of Clinical Practice
Medicine
2008English

Cost-Effectiveness of Rapid Susceptibility Testing Against Second-Line Drugs for Tuberculosis

International Journal of Tuberculosis and Lung Disease
MedicinePulmonaryInfectious DiseasesRespiratory Medicine
2014English

Pay-For-Performance or Compliance? A Second Opinion on Medicare Reimbursement

Indiana Health Law Review
2006English

A "Second Opinion" on the Economic Health of the American Middle Class

2011English

Effectiveness of Second-Line Agents in the Treatment of Uncomplicated Type 2 Diabetes Mellitus: An Observational Tertiary-Care Based Study

Journal of Young Pharmacists
ToxicologyPharmaceuticsPharmacology
2018English

Anti-Angiogenic Drugs for Second-Line Treatment of NSCLC Patients: Just New Pawns on the Chessboard?

Expert Opinion on Biological Therapy
Drug DiscoveryClinical BiochemistryPharmacology
2015English

Simulating Second-Guessing in On-Line Probability Learning

Behavior Research Methods
DevelopmentalArtsPsychologyEducational PsychologyCognitive PsychologyHumanitiesExperimental
1981English

Second-Line Option for Colorectal Cancer

Cancer Discovery
Oncology
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy